Pócsik E, Mihalik R, Réti M, Gyódi E, Pálóczi K, Mayer K, Kassai M, Herold M, Huber C, Petrányi G G
National Institute of Haematology and Blood Transfusion, Budapest, Hungary.
Immunobiology. 1990 Dec;182(1):22-31. doi: 10.1016/S0171-2985(11)80580-2.
MHC-unrestricted cytotoxic activity of peripheral blood lymphocytes (PBL) from 4-6 healthy donors was investigated before and after transfusion with allogeneic leukocytes or platelets. Natural killer and lectin-dependent cellular cytotoxicity (LDCC) of PBL was tested against K562 and Raji target cells in a 4-h and 16-h 51Cr-release assay, respectively. After allotransfusion with leukocytes, we found increased cytotoxic activity of each donor's PBL against all the three targets on day 3 or 7. The highest non-specific cytotoxic activity was detected against the relatively NK resistant Raji target cells. The increase of cytotoxic activity was lowest against the LDCC target (PHA-treated Raji) cells. On the contrary, no changes in cytotoxic activity against any targets were observed after allotransfusion with platelets (possessing class I HLA antigens but no HLA class II molecules). Our results suggest that HLA class II molecules, presumably by inducing immune responses, are essential for activation/generation of non-specific killing of tumor targets after leukocyte transfusion. Thrombocytes, known to be less immunogenic than leukocytes, are not effective in in vivo enhancing of non-specific cytotoxicity. Cellular activation of PBL following leukocyte allotransfusion was confirmed by detection of elevated serum neopterin and beta-2-microglobulin levels on day 3. This was not the case after platelet allotransfusion. In addition, the expression of ICAM-1 antigen (as a molecule involved directly in MHC-unrestricted cytotoxicity) was also found to be increased in two donors' PBL on day 3 after leukocyte transfusion in contrast to transfusion with platelets.
对4 - 6名健康供体的外周血淋巴细胞(PBL)在输注异体白细胞或血小板前后的MHC非限制性细胞毒性活性进行了研究。分别在4小时和16小时的51Cr释放试验中,检测PBL对K562和Raji靶细胞的自然杀伤和凝集素依赖性细胞毒性(LDCC)。白细胞异体输血后,我们发现每个供体的PBL在第3天或第7天对所有三个靶标的细胞毒性活性增加。对相对NK抗性的Raji靶细胞检测到最高的非特异性细胞毒性活性。对LDCC靶标(PHA处理的Raji)细胞的细胞毒性活性增加最低。相反,血小板(具有I类HLA抗原但无HLA II类分子)异体输血后,未观察到对任何靶标的细胞毒性活性变化。我们的结果表明,HLA II类分子可能通过诱导免疫反应,对于白细胞输血后肿瘤靶标的非特异性杀伤的激活/产生至关重要。已知血小板的免疫原性低于白细胞,在体内增强非特异性细胞毒性方面无效。白细胞异体输血后PBL的细胞活化通过第3天血清新蝶呤和β2 -微球蛋白水平升高得以证实。血小板异体输血后情况并非如此。此外,与血小板输血相比,白细胞输血后第3天,两名供体的PBL中ICAM - 1抗原(作为直接参与MHC非限制性细胞毒性的分子)的表达也增加。